As per ChatGPT so it must be true :)2013–2019: Focus on...

As per ChatGPT so it must be true

2013–2019: Focus on HER-Vaxx

Imugene's primary focus during this period was the development of HER-Vaxx, a B-cell peptide vaccine targeting HER2-positive cancers, particularly gastric cancer.HER-Vaxx is designed to stimulate the body's immune system to produce polyclonal antibodies against the HER2 receptor, offering a potential alternative to monoclonal antibody therapies like trastuzumab.aacrjournals.orgresearchgate.net+5biospace.com+5dalmatian-minnow-lzgc.squarespace.com+5

The company initiated a Phase Ib clinical trial for HER-Vaxx, which demonstrated safety and the ability to induce HER2-specific antibodies.Following these results, a Phase II trial was launched in 2019 to further evaluate its efficacy in combination with chemotherapy.imugene.comaacrjournals.org

2019 Onwards: Expansion of the B-cell Platform

In 2019, Imugene expanded its B-cell immunotherapy platform by licensing PD1-Vaxx, a vaccine targeting the PD-1 checkpoint protein.This addition marked a significant broadening of their immuno-oncology pipeline.imugene.com+2en.wikipedia.org+2imugene.com+2

Summary

Between 2013 and 2019, Imugene was not idle; the company was actively developing and advancing HER-Vaxx through clinical trials.The B-cell platform's expansion in 2019 with PD1-Vaxx represented a strategic move to diversify and strengthen their immunotherapy portfolio.